Pharmaceutical News and Articles

FDA Approves TNKase (tenecteplase) for the Treatment of Acute Ischemic Stroke in Adults

CDC IDs Trends in Pediatric Flu Deaths With Influenza-Linked Encephalopathy

During the 2010-2011 to 2024-2025 influenza seasons, 9 percent of pediatric influenza-associated deaths had influenza-associated encephalopathy or encephalitis

Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies

Genentech, a member of the Roche Group (SIX RO, ROG OTCQX RHHBY), announced today new positive data from Stage 2 and Stage 3 of the National Institutes of Healt

Omalizumab Treats Multi-Food Allergy Better Than Oral Immunotherapy

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in peop

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

NEWARK, California, OSAKA, Japan and CAMBRIDGE, Massachusetts, March 3, 2025 Protagonist Therapeutics, Inc. ( Protagonist ) (NASDAQ PTGX) and Takeda (TSE 4502 N

Longtime NIH Leader Francis Collins Retires

Dr. Francis Collins, the famed geneticist who led the National Institutes of Health (NIH) for 12 years and helped guide the U.S. through the COVID pandemic, has

Duke Doctors Perform First Living Mitral Valve Transplant

In a groundbreaking series of surgeries, doctors at Duke Health have successfully performed the world s first living mitral valve replacement, saving the lives

Electric Vehicle Fires May Raise Cancer Risk for Communities

As electric vehicles (EVs) become more common on roads, they bring new health concerns for firefighters and the community, new research shows. Researchers at th

Psychosomatic Misdiagnosis Can Have Lasting Negative Impact on Patients

Chronic diseases misdiagnosed as psychosomatic can lead to long-term damage to patients physical and mental well-being, according to a study published online Ma

Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors

For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium-glucose co-transporter (SGLT)-1 2 inhibit